Metformin Associated Lactic Acidosis in the Intensive Care Unit: A Rare Condition Mimicking Sepsis

Selin Sendil ¹, Keerthi Yarlagadda ¹, Halimat Lawal ¹, Vinod Nookala ², Hiren Shingala ³

1. Internal Medicine, University of Pittsburgh Medical Center (UPMC) Pinnacle, Harrisburg, USA  
2. Internal Medicine, Community Medical Center, Toms River, USA  
3. Critical Care Medicine, University of Pittsburgh Medical Center (UPMC) Pinnacle, Harrisburg, USA

Corresponding author: Selin Sendil, sendils@upmc.edu

Abstract

Metformin-associated lactic acidosis (MALA) is a rare but serious complication of metformin use, associated with high mortality. MALA can occur any time a patient on metformin suffers disruption in renal function resulting in the accumulation of metformin.

A 63-year-old man with a history of non-insulin-dependent type 2 diabetes mellitus, alcohol abuse, and hypothyroidism was brought to the emergency department with altered mental status, nausea, vomiting, and abdominal pain. He was found to be in respiratory distress, was hypotensive and hypoglycemic (48 mg/dL), and required emergent intubation. Blood work was significant for pH<6.69, undetectable bicarbonate, anion gap 37.2 mEq/L, lactate >12 mmol/L, creatinine 15.95 mg/dL, blood urea nitrogen (BUN) 112 mg/dL, glomerular filtration rate (GFR), 3 ml/min/1.73sqm, and potassium 7 mmol/L. He suffered cardiac arrest, underwent cardiopulmonary resuscitation (CPR), and was admitted to the intensive care unit (ICU) where he required multiple vasopressors, bicarbonate infusion, and bicarbonate pushes. He was started on continuous renal replacement therapy with a high flux membrane. A high dose of pre- and post- filter fluids was used to improve conductive clearance. His pH corrected to normal in less than 24 hours, and hemodialysis was initiated the following day for a total of four days. Head/chest/abdomen/pelvis CT, urine, and blood cultures did not reveal any pathology that would explain lactic acidosis. The patient’s dose of metformin was 1 gr twice daily and sitagliptin, 100 mg daily. Blood metformin that had been tested on admission was 29 mcg/ml (therapeutic range, 1-2 mcg/ml). Methanol, ethanol, ethylene glycol, propylene glycol, and isopropanol levels were negative. He had been started on lisinopril 5 mg and amitriptyline 25 mg four weeks prior to admission and had normal creatinine at that time. He was discharged to an acute rehabilitation facility on day seven of hospitalization.

MALA generally presents with nausea, vomiting, and fatigue—often mimicking sepsis. It is possible that our patient progressively developed alcoholic ketoacidosis and acute renal failure from dehydration and excessive drinking in the setting of newly started Angiotensin-converting-enzyme (ACE) inhibitor. Recommendations for the optimal treatment of MALA mostly depend on expert opinion and case reports. Treatment is restricted to supportive measures, although hemodialysis may offer a protective effect. Our case demonstrates that even in extreme cases of MALA, prompt and adequate supportive measures can produce a favorable outcome.

Categories: Emergency Medicine, Internal Medicine, Nephrology  
Keywords: metformin associated lactic acidosis, mala, metformin, renal failure, crrt

How to cite this article
Sendil S, Yarlagadda K, Lawal H, et al. (July 10, 2020) Metformin Associated Lactic Acidosis in the Intensive Care Unit: A Rare Condition Mimicking Sepsis. Cureus 12(7): e9119. DOI 10.7759/cureus.9119
Introduction

Metformin-associated lactic acidosis (MALA) is a rare but potentially fatal complication of metformin use with a 30-50% mortality rate [1]. MALA can occur anytime a patient on metformin suffers a disruption in renal function resulting in an accumulation of metformin. Here, we present a case of a 63-year-old male with non-insulin-dependent type II diabetes mellitus (NIDDM) on metformin who developed severe lactic acidosis, profound acidemia, significant electrolyte abnormalities, and ultimately cardiac arrest in the setting of acute kidney injury (AKI).

Case Presentation

A 63-year-old Caucasian male with a past medical history of NIDDM, alcohol use disorder, anxiety, and hypothyroidism was brought to the emergency department (ED) via emergency medical services (EMS) with altered mental status. He had reportedly been having nausea, vomiting, and abdominal pain for one week, and also developed progressively worsening change in vision for about 48 hours. Initially, EMS found his blood glucose 48 mg/dL and administered intravenous (IV) dextrose. Upon arrival at the ED, he was found to be in respiratory distress with labored breathing and respiratory rate of 22/minute. His heart rate was 63 beats per minute, blood pressure 47/33 mmHg, temperature 92.6 °F (rectal temperature). The patient required emergent intubation in the ED. His initial blood work was significant for pH<6.69 (could not be calculated by our institution’s blood gas analyzer), undetectable bicarbonate (could not be calculated by our institution’s blood gas analyzer), anion gap 37.2 mEq/L, lactate >12 mmol/L, creatinine 15.95 mg/dL, blood urea nitrogen (BUN) 112 mg/dL, glomerular filtration rate (GFR) 3 ml/min/1.73sqm, phosphorus 17.7 mmol/L, potassium 7 mmol/L (Table 1).
His white blood cell count (WBC) was 9.5 K/µL, neutrophils 50%, band 6% (Table 2), activated partial thromboplastin time 79.3 seconds, and international normalized ratio 1.1. He developed cardiac arrest in the ED, received brief cardiopulmonary resuscitation (CPR) with a return of spontaneous circulation (ROSC), and was admitted to the intensive care unit (ICU). He required multiple vasopressors and bicarbonate infusion in addition to several bicarbonate pushes. He was started on continuous renal replacement therapy (CRRT) with a high flux membrane. High dose of pre- and post- filter fluids was used to improve conductive clearance. CRRT was chosen over hemodialysis due to hemodynamic instability. His pH corrected to normal levels with CRRT in less than 24 hours (Table 3). He was transitioned to hemodialysis the following day. His lactic acid and bicarbonate levels improved to normal levels in 48 hours.

---

**TABLE 1: The patient’s BMP from a month ago and the BMP obtained in the ED**

| Parameters          | BMP a month prior to presentation | BMP after initial stabilization |
|---------------------|----------------------------------|--------------------------------|
| Sodium (mmol/L)     | 140                              | 131                            |
| Potassium (mmol/L)  | 4.4                              | 7                              |
| Chloride (mmol/L)   | 105                              | 89                             |
| CO₂ (mmol/L)        | 25.9                             | 4.8                            |
| Anion Gap (mEq/L)   | 9.1                              | 37.2                           |
| BUN (mg/dL)         | 14                               | 112                            |
| Creatinine (mg/dL)  | 0.81                             | 15.95                          |
| GFR (ml/min/1.73sqm)| >90                              | 3                              |
| Phosphorus (mg/dL)  |                                  | 17.7                           |
| Glucose (mg/dL)     | 119                              | 138                            |
| Calcium (mg/dL)     | 9.3                              | 7.8                            |
| ALP (U/L)           | 123                              | 72                             |
| ALT (U/L)           | 14                               | 17                             |
| AST (U/L)           | 16                               | 21                             |
| Total Bilirubin (mg/dL) | 0.3                        | 0.3                            |
| Total Protein (g/dL)| 6.7                              | 5.1                            |
| Albumin (g/dL)      | 3.9                              | 3                              |

BMP: basic metabolic panel; BUN: blood urea nitrogen; GFR: glomerular filtration rate; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ED: emergency department
| Parameters              | Values  |
|------------------------|---------|
| WBC (K/uL)             | 9.5     |
| RBC (M/uL)             | 3.91    |
| Hemoglobin (g/dL)      | 11.6    |
| Hematocrit (%)         | 39      |
| MCV (FL)               | 99.8    |
| Platelet Count (K/uL)  | 318     |
| RDW (%)                | 16.3    |
| Neutrophils (%)        | 49.5    |
| Band (%)               | 5.7     |
| Lymphocytes (%)        | 33.3    |
| Monocytes (%)          | 1       |
| Metamyelocytes (%)     | 8.6     |
| Myelocytes (%)         | 1.9     |
| Anisocytosis           | 1+      |

TABLE 2: The patient’s CBC on presentation

CBC: complete blood count; WBC: white blood cell; RBC: red blood cell; MCV: mean corpuscular volume; RDW: the red cell distribution width
| Parameters     | ABG on presentation (intubated) | ABG after 24 hours on CRRT (intubated) |
|----------------|---------------------------------|---------------------------------------|
| pH Art         | <6.69                           | 7.42                                  |
| pCO₂           | 40.4                            | 34.7                                  |
| pO₂            | 138                             | 94                                    |
| HCO₃           | could not calculate             | 22.9                                  |
| Base Excess    | could not calculate             | 1                                     |

**TABLE 3: The patient’s initial ABG and the much-improved ABG on CRRT in less than 24 hours**

ABG: arterial blood gas

The patient’s urine and blood cultures did not grow any microorganism. Chest x-ray (CXR) did not show any acute cardiopulmonary process. His head computed tomography (CT) did not show any acute abnormality. CT chest abdomen pelvis did not reveal any acute pathology that can explain the patient’s severe lactic acidosis. The patient was on metformin 1 gram twice daily and sitagliptin 100 mg daily at home prior to this hospitalization. A blood metformin level was sent on admission and came back as 29 mcg/ml (therapeutic range 1-2 mcg/ml). Methanol, ethanol, ethylene glycol, propylene glycol, and isopropanol levels came back negative (Table 4).
| Toxicology panel                  | Values | Reference range                  |
|----------------------------------|--------|----------------------------------|
| Metformin                        | 29     | 1-2 mcg/mL                       |
| Salicylate                       | <2.5   | <2.5                             |
| Acetaminophen                    | <10    | <10                              |
| Desipramine                      | <5     | Therapeutic range changes        |
| Imipramine                       | <5     | Therapeutic range changes        |
| Amitriptyline                    | 18     | Therapeutic range changes        |
| Doxepin                          | <5     | Therapeutic range changes        |
| Doxepin Total                    | <5     | Therapeutic range changes        |
| Nordoxepine                      | <5     | Therapeutic range changes        |
| Total Amitriptyline and Nortriptyline | 31  | 100 - 250 mcg/L                  |
| Desmethylclomipramine            | <5     | 150 - 350 mcg/L                  |
| Total Clomipramine               | None detected | Unknown                          |
| Methanol                         | <0.01  | <0.01                            |
| Ethylene glycol                  | 20     |                                  |
| Isopropanol                      | <0.01  | <0.01                            |
| Acetone                          | 140    | <100 = negative, >150 = acetone metabolic imbalance |

**TABLE 4: Toxicology panel showing significantly elevated blood levels of metformin**

A review of the patient’s electronic medical records revealed that he was started on lisinopril 5 mg daily and amitriptyline 25 mg daily four weeks prior to this admission and had normal kidney function (BUN, creatinine, GFR) at that time. His renal function normalized within four days, and he did not need hemodialysis after that. He was ultimately discharged to an acute rehabilitation facility on day seven of hospitalization.

**Discussion**

Metformin is a widely used biguanide anti-diabetic medication with multiple mechanisms of action, which decreases insulin resistance and hepatic glucose output; it enhances peripheral glucose uptake with net effects of decreasing fasting and post-prandial blood glucose [2]. These overall benefits make it the first-line drug as it does not cause hypoglycemia as often as the most other classes of oral anti-diabetic medications. Although generally considered as safe, metformin’s most serious but rare side effect is MALA. The mechanism of MALA is complex. Metformin promotes the conversion of glucose to lactate in the splanchnic bed of the small intestine and also inhibits mitochondrial respiratory chain complex 1, leading to decreased hepatic gluconeogenesis from lactate, pyruvate, and alanine resulting in additional lactate and substrate for lactate production. In the absence of acute overdose, metformin-associated lactic
Acidosis rarely develops in patients without comorbidities such as renal or hepatic insufficiency or acute infection. However, in the rare circumstance when metformin-associated lactic acidosis develops, mortality is high [1,3]. Higher mortality was associated with increased age, lower arterial pH, elevated prothrombin time, and need for mechanical ventilation and vasoactive medications [4].

MALA can occur any time a patient on metformin suffers disruption in renal function resulting in the accumulation of metformin. MALA generally presents with nausea, vomiting, and fatigue, mimicking sepsis [5]. Reportedly, the patient was complaining of nausea, vomiting, and abdominal pain for a few days prior to presentation. Interestingly, he was also complaining of ‘tunnel vision’ to his family. In this case, the patient was found to have a severe anion gap metabolic acidosis with a massively elevated lactic acid despite an acceptable blood pressure, benign abdominal examination, and lack of fever. It is not necessarily due to impaired tissue perfusion, but rather to interference with ATP production. In our patient, the elevation in lactic acid was due, in part, to the accumulation from hepatic gluconeogenesis inhibition and, more importantly, accumulation of NADH (from oxidative phosphorylation inhibition) which results in shunting of pyruvate to lactate (in lieu of acetyl-CoA). It is possible that our patient progressively developed alcoholic ketoacidosis and acute renal failure from dehydration and excessive drinking in the setting of a newly started angiotensin-converting enzyme (ACE) inhibitor. This could have been the initial insult, but since ethylene glycol toxicity could not be ruled out without levels, he was also treated with fomepizole. If presentation delayed enough, ethylene glycol level might actually be normal given that it is not ethylene glycol itself, which causes toxicity but rather its metabolites glycolic acid and oxalic acid. However, given the history, AKI, and renal failure from dehydration may be more likely. The report of vision changes brought to mind methanol toxicity. However, renal failure is not common. As suspected, blood metformin levels sent during the initial presentation came back significantly elevated at 29 mcg/ml (therapeutic range: 1-2 mcg/ml).

Recommendations for the optimal treatment of MALA mostly depend on expert opinion and case reports. Initial treatment is restricted to supportive measures, although hemodialysis may offer a protective effect [1,5,6]. Metformin is exclusively renally cleared. While metformin is not typically considered a ‘dialyzable’ drug due to its high volume of distribution, there is no other alternative [6]. In our patient, we chose to proceed with CRRT due to significant hemodynamic instability requiring multiple vasopressors at the maximum doses. However, as soon as his hemodynamics improved, he was switched to hemodialysis. Ultimately, in less than 24 hours, his pH improved to normal physiologic limits. Our case demonstrates that even in extreme cases of MALA, prompt and adequate supportive measures can produce a favorable outcome.

Conclusions

Although rare, MALA can be encountered in the ICU and continues to be a life-threatening condition. In view of current literature, recommendations for the optimal treatment of MALA depend on expert opinion and case reports. Treatment is restricted mostly to supportive measures, although hemodialysis may possess a protective effect. Our case demonstrates that even in extreme cases of MALA, with the prompt and adequate supportive measures, a favorable outcome is possible. More studies with larger patient populations are needed to reach definitive and data-driven recommendations on the treatment of MALA.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from
any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Peters N, Jay N, Barraud D, Cravoisy A, Nace L, Bollaert PE, Gibo S: Metformin-associated lactic acidosis in an intensive care unit. Crit Care. 2008, 12:149. 10.1186/cc7137
2. Sirtori CR, Pasik C: Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res. 1994, 30:187-228. 10.1016/1043-6618(94)80104-5
3. Lalau JD, Race JM: Lactic acidosis in metformin treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf. 1999, 20:377-384. 10.2165/00002018-199920040-00006
4. Seidowsky A, Nseir S, Houdret N, Fourrier F: Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med. 2009, 37:2191-2196. 10.1097/ccm.0b013e3181a02490
5. Umeda T, Minami T, Bartolomei K, Summerhill E: Metformin-associated lactic acidosis: a case report. Drug Saf Case Rep. 2018, 5:8. 10.1007/s40800-018-0076-1
6. Calello D, Liu KD, Wiegand TJ, et al.: Extracorporeal treatment for metformin poisoning: systematic review and recommendations from the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med. 2015, 43:1716-1730. 10.1097/CCM.0000000000001002